KRYS News and Press, Krystal Biotech Inc. From 11/06/23

2023-11-06 11:43:02 ET Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Conference Call November 06, 2023 08:30 A.M. ET Company Participants Meg Dodge - VP, Investor Relations & Corporate Communications Krish Krishnan - Chairman & Chief Executive Officer Suma...

2023-11-06 07:07:09 ET More on Krystal Biotech Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement Cantor starts Krystal Biotech at overweight, cites Vyjuvek launch Seeking Alpha’s Quant Rating on Krystal Biotech Historical earnin...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Krystal Biotech Inc. (KRYS) is expected to report $-1.1 for Q3 2023

2023-11-05 11:08:50 ET Major earnings expected before the bell on Monday include: Axsome Therapeutics ( AXSM ) Brookfield Asset Management ( BAM ) BioNTech ( BNTX ) Ceragon Networks ( CRNT ) DISH Network ( DISH ) For further details see: N...

2023-11-03 11:34:51 ET More on Krystal Biotech Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement Cantor starts Krystal Biotech at overweight, cites Vyjuvek launch Krystal Biotech wins FDA nod to run trial for gene therapy Seeking Alpha...

PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, will...

2023-10-25 19:00:31 ET More on Krystal Biotech Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement Krystal Biotech: Pioneering Rare Disease Gene Therapies Krystal Biotech wins FDA nod to run trial for gene therapy Berenberg starts Krysta...

PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, ann...

2023-09-22 09:54:38 ET Summary Krystal Biotech, Inc. received FDA approval of Vyjuvek, for the treatment of patients with dystrophic epidermolysis bullosa in May of 2023. FDA IND clearance of KB408 for the treatment of patients with antitrypsin deficiency given; Phase 1 study expe...